NABP Pulse Expands Product Verification Features for Wholesale Drug Distributors

The National Association of Boards of Pharmacy (NABP) announced expanded product verification capabilities within its Pulse platform on January 15, 2025. The enhancements allow wholesale drug distributors and third-party logistics providers to verify product serialization data directly against manufacturer records, addressing a functional gap in Drug Supply Chain Security Act (DSCSA) compliance workflows that previously required manual cross-referencing across multiple systems.

Regulatory Context

The DSCSA, codified at 21 U.S.C. § 360eee et seq., mandates interoperable, electronic tracing of prescription drugs through the distribution chain. As of November 27, 2024, wholesale distributors must maintain transaction information, transaction history, and transaction statements (TI/TH/TS) in electronic format. By November 27, 2027, the law requires full unit-level tracing using serialized product identifiers.

NABP operates the Pulse platform as part of its broader verification system for pharmaceutical supply chain participants. The platform previously supported licensure verification and VAWD (Verified-Accredited Wholesale Distributors) status checks. Product-level verification capabilities were limited to batch/lot lookup against FDA recall databases. The January 2025 expansion adds direct serialization verification—a function increasingly critical as the 2027 unit-level tracing deadline approaches.

Key Details of the Expansion

The expanded Pulse functionality includes three primary features:

1. Serialization Cross-Reference: Distributors can query a product's 10-digit National Drug Code (NDC), serial number, lot number, and expiration date against a centralized repository of manufacturer-reported data. The system returns a pass/fail verification within 2-3 seconds.

1. Aggregated Transaction History (ATH) Access: Wholesale distributors can retrieve the full transaction history for a serialized product, including prior trading partner identities and transaction dates. This addresses the DSCSA requirement under 21 U.S.C. § 360eee-1(c)(4) that distributors must be able to provide transaction information within three business days of a request.

1. Saleable Returns Verification: The platform now supports verification of product eligibility for saleable returns under 21 CFR § 203.23. Distributors can confirm whether a returned product's serial number matches the original dispensed unit and whether it remains within dating specifications.

NABP states the system currently integrates serialization data from 47 pharmaceutical manufacturers representing approximately 62% of U.S. prescription drug volume by unit. Data ingestion follows the GS1 EPCIS (Electronic Product Code Information Services) standard, the format required by DSCSA for interoperable tracing.

Operational Impact for Wholesale Distributors

The verification features address three compliance pain points:

Due Diligence on Incoming Product: Under 21 U.S.C. § 360eee-1(d)(1)(B), distributors must verify that received products are not counterfeit, diverted, or otherwise illegitimate. Manual verification processes—cross-referencing product serial numbers against Excel files or PDF transaction statements—have been operationally cumbersome and error-prone. Pulse's automated lookup reduces verification time from 5-10 minutes per line item to under 10 seconds.

Saleable Returns Processing: Distributors handling returns from pharmacies must confirm product authenticity and custody chain before reselling. The previous standard of practice involved contacting the manufacturer directly or relying on paper documentation. Pulse's saleable returns module provides independent third-party verification, reducing the time required to clear a returned product for redistribution.

Regulatory Response Preparedness: FDA may request transaction history during inspections or investigations under 21 U.S.C. § 360eee-2. Distributors without centralized systems have struggled to aggregate TI/TH/TS data across multiple trading partners within the three-day statutory response window. Pulse's ATH access provides a single query point for multi-hop transaction histories, assuming participating manufacturers have uploaded complete data.

The expansion does not replace DSCSA compliance obligations. Distributors remain responsible for maintaining their own transaction records under 21 U.S.C. § 360eee-1(b)(1)(A). Pulse functions as a verification layer, not a substitute for internal systems.

What ColdChainCheck Data Shows

Of the 1,275 wholesale drug distributors and 3PLs tracked in ColdChainCheck's directory, only 63 hold active NABP accreditation (formerly VAWD). This 4.9% accreditation rate suggests limited current engagement with NABP verification systems across the broader distributor population. The expanded Pulse features may increase adoption if manufacturers begin requiring verification through the platform as part of trading partner qualification.

The average compliance score across all tracked entities is 51/100, placing the industry median in the "Fair" tier. ColdChainCheck's scoring methodology allocates 25 points for NABP accreditation status. Entities without accreditation cannot currently earn these points, regardless of licensure strength in other categories. If Pulse adoption becomes a de facto industry standard for DSCSA product verification, the gap between accredited and non-accredited distributors may widen in terms of operational efficiency and trading partner acceptability.

73 entities in the directory have at least one FDA recall on record. For these distributors, the saleable returns verification feature represents a direct compliance tool. Product recalls often trigger heightened scrutiny of transaction history—both from FDA investigators and from downstream trading partners conducting post-recall reconciliation. The ability to independently verify product custody chain through Pulse may reduce the administrative burden of responding to recall-related inquiries.

Practical Guidance for QA and Compliance Teams

• Verify NABP accreditation status of current trading partners: Use the ColdChainCheck directory to confirm which distributors in your supply chain hold active NABP accreditation. Entities without accreditation cannot access Pulse verification features. If your organization relies on serialization verification for incoming product checks, ask non-accredited partners how they plan to support comparable functionality.

• Assess manufacturer participation in Pulse: NABP reports 47 manufacturers currently contribute serialization data, covering 62% of prescription drug volume. For products from non-participating manufacturers, Pulse verification will return no data. Identify which of your product lines fall outside this coverage and maintain alternative verification processes for those SKUs.

• Document verification processes for audit readiness: FDA inspections under 21 CFR Part 205 increasingly focus on how distributors verify product authenticity. Whether your organization uses Pulse, a proprietary verification system, or manual processes, ensure your SOPs specify the verification method and document each check. ColdChainCheck's DSCSA compliance checklist covers documentation requirements for wholesale distributor inspections.

• Monitor enforcement patterns: ColdChainCheck tracks FDA warning letters and enforcement actions. 38 entities in the directory currently score in the "Poor" range (25-40 points), often reflecting expired licenses or enforcement history. Review the enforcement data to identify whether product verification gaps appear as a recurring citation pattern in recent FDA actions.

Disclaimer: This article is provided for informational purposes only and does not constitute legal or regulatory advice. Wholesale drug distributors should consult with qualified legal counsel and verify all regulatory requirements with the appropriate state boards of pharmacy and federal agencies.